SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

X4 Pharmaceuticals Outlines Mavorixafor Development Milestones

X4 said pivotal Phase 3 data are expected in Q1 2028, with potential U.S. approval in late 2028 or early 2029.

XFOR

Related stories